Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanest in cancer chronic pain
NCT00959400Phase 3Withdrawn
- Sponsor
- Cristália
- Start
- Nov 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Cynril in cancer pain, sponsored by Cristália. Primary endpoints: Formulation tolerability (assessed by adverse events incidence) at 4 weeks and Formulation analgesic efficacy (assessed by rescue medication demand) at 4 weeks. Planned start Nov 2009; status: withdrawn.
02
Drugs
Cynril
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00959400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00959400.